Thu 13th Aug 2020 @ 6:00am - 7:00am
Why you should care, and what we are going to do.
Featuring: Prof. Yaakov Nahmias
Could a simple drug, that has been on the market for decades, be used to treat COVID-19? A research team led by Prof. Yaakov (Koby) Nahmias says that early research looks promising. The team has looked at how COVID-19 changes patients’ lungs in order to reproduce itself. Their major finding? This virus prevents the routine burning of carbohydrates. As a result, large amounts of fat accumulate inside lung cells, a condition the virus needs in order to reproduce. This new understanding may help explain why patients with high blood sugar and cholesterol levels are often at a particularly high risk to develop COVID-19.
Who Will You See There?
Professor Yaakov (Koby) Nahmias is a bioengineer and innovator, whose breakthroughs ranged from the first 3D printing of cells to the first commercial human-on-chip technology. He is a Magna Cum Laude graduate of the Technician, Israel Institute of Technology, and is the founding director of the Grass Center for Bioengineering of the Hebrew University of Jerusalem.
Nahmias is a recipient of a NIH career award, two European Research Council (ERC) grants, the Kaye Innovation Award and the prestigious Rappaport Prize in Biomedical Research. He is the first scientist outside Britain to win the Rosetrees Trust Prize. Koby is a fellow of both the prestigious American Institute for Medical and Biological Engineering (AIMBE) and the British Royal Society of Medicine (RSM). He is an editorial board member of the Annual Reviews for Biomedical Engineering, and a long-standing member of the European Research Council LS9 Biotechnology committee. Nahmias is the founding director of BioDesign-Israel, an entrepreneurship program sponsored by Boston Scientific that spun off several medical device companies including Guide In Medical, CardioVia and VenoVision.
Future Meat Technologies is a Food-Tech company advancing a distributive manufacturing platform for the cost-efficient, non-GMO production of meat directly from animal cells, without the need to raise or harvest animals. Future Meat Technologies focuses on developing a new generation of manufacturing technology that enables the cost-efficient production of fat and muscle cells, the core building blocks of meat. The technology is exclusively licensed from the Hebrew University of Jerusalem, based on Koby’s research.
COVID-19, Metabolism and your lungs